SEARCH

Search Details

sekizaki tomonori

Hokkaido University Hospital Internal Medicine Diabetes and EndocrinologySpecially Appointed Assistant Professor

Researcher basic information

■ URL
researchmap URLホームページURL■ Various IDs
J-Global ID

Research activity information

■ Papers
  • Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas
    Tomonori Sekizaki; Hiraku Kameda; Akinobu Nakamura; Saki Kuwabara; Hiroshi Nomoto; Kyu Yong Cho; Yukitomo Ishi; Hiroaki Motegi; Hideaki Miyoshi; Tatsuya Atsumi
    Pituitary, 26, 5, 597, 610, Springer Science and Business Media LLC, 29 Aug. 2023, [Peer-reviewed], [Lead author]
    English, Scientific journal
  • Dipeptidyl peptidase‐4 inhibitor might exacerbate Graves’ disease: A multicenter observational case–control study
    Tomonori Sekizaki; Hiraku Kameda; Hiroshi Nomoto; Kyu Yong Cho; Akinobu Nakamura; Kiyohiko Takahashi; Arina Miyoshi; Norio Wada; Jun Takeuchi; So Nagai; Hideaki Miyoshi; Tatsuya Atsumi
    Journal of Diabetes Investigation, 12, 11, 1978, 1982, Wiley, 16 Jun. 2021, [Peer-reviewed], [Lead author]
    English, Scientific journal, Abstract

    Dipeptidyl peptidase‐4 (DPP‐4), namely CD26, is expressed on the surface of immune cells, suggesting that inhibition of DPP‐4 might affect the immune system. The current multicenter observational case–control study was carried out to investigate the effects of DPP‐4 inhibitor (DPP‐4i) administration on Graves' disease (GD) activity. This study comprised patients with GD and type 2 diabetes, who were administered an oral hypoglycemic agent including DPP‐4i. Exacerbation of GD was defined as an increase of antithyroid drug dose by 6 months after oral hypoglycemic agent administration. A total of 80 patients were enrolled and divided into an exacerbation group or a non‐exacerbation group. The frequency of DPP‐4i administration was significantly higher in the exacerbation group (88%) than that in the non‐exacerbation group (31%). In multivariate logistic regression analysis, there was a significant association between DPP‐4i administration and GD exacerbation (odds ratio 7.39). The current study suggests that DPP‐4i administration is associated with GD exacerbation.
■ Other Activities and Achievements